US Compounding develops compound to manage equine ulcersDecember 8, 2017Adamis Pharmaceuticals Corp. announced that its subsidiary, US Compounding, has developed a compound to manage ulcers in horses. A study, utilizing US Compounding's drug formulation, was conducted in approximately 50 racehorses. Gastric endoscopy was performed at Day 0 and any time between Days 14 and 21. The drug was administered after the first endoscopy as a paste given orally for 30 days. Endoscopic improvement was seen as early as 14 days. In more than 95 percent of the horses, the ulcers were shown to be clinically healed, as confirmed by endoscopy, with a reduction in gastric ulcer recovery times. The company has filed a patent application covering the compounded product; a manuscript is in preparation.
Education Center - SponsoredWhere next for point-of-care diagnostics?by • Zoetis Diagnostics USPoint-of-care diagnostics are rapidly evolving. Complete blood counts and cytology evaluations are no longer confined to reference laboratories – veterinarians can now run these tests in clinic, with artificial intelligence-powered tools. This shift is bringing expert-level care to general practice, streamlining workflows and driving better patient care. Hear from Zoetis leaders on how point-of-care diagnostic technologies are transforming veterinary practice, helping to empower teams, broaden access to care, and improving patient outcomes.
